Natera, Inc. announced that the American Journal of Transplantation (AJT) published a new study evaluating the performance of Prospera Heart with Donor Quantity Score (DQS) to detect allograft rejection. This publication adds to the growing body of evidence supporting DQS for donor-derived cell-free DNA (dd-cfDNA) analysis.
The study demonstrated that combining dd-cfDNA percentage with DQS improved the accuracy of dd-cfDNA testing for acute rejection compared to using dd-cfDNA percentage alone. This method resulted in an increase in the area under the curve (AUC) from 0.865 to 0.881.
A significant improvement highlighted by the study was a greater than 37% reduction in false positive cases when using Prospera Heart with DQS. This enhanced accuracy has the potential to reduce unnecessary biopsies in clinical care, improving patient experience and outcomes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.